US67080T1088
US67080T1088
Nuvectis Pharma, Inc.
Loading chart...
Valuation & History
Quarterly trend of key valuation metrics
| Metric | Current (TTM) TTM Baseline | Q2 '26 30.06.2026 | Q1 '26 31.03.2026 | Q4 '25 31.12.2025 |
|---|---|---|---|---|
Market & Enterprise Value | ||||
Market Cap | 689.44M EUR | 490.92M EUR | 205.04M EUR | 193.86M EUR |
Enterprise Value | 633.71M EUR | 468.76M EUR | 179.91M EUR | 162.23M EUR |
Valuation Multiples | ||||
Trailing P/E | -- | -- | -- | -- |
Forward P/E | -22x | -- | -- | -- |
Price to Sales | -- | -- | -- | -- |
Price to Book | 62.12x | 54.05x | 14.42x | 10.53x |
EV/Revenue | -- | -- | -- | -- |
EV/EBITDA | -- | -- | -- | -- |
Price to FCF (P/FCF) | -- | -- | -- | -- |
EV/FCF | -- | -- | -- | -- |
FCF Yield | -1.29% | -3.97% | -8.95% | -6.1% |